{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:41:50Z","timestamp":1789846910399,"version":"4.0.1"},"reference-count":22,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00161","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T22:06:14Z","timestamp":1498860374000},"page":"1116-1120","source":"Crossref","is-referenced-by-count":21,"title":["Amelioration of the Development of Osteoarthritis by Daily Intake of \u03b2-Cryptoxanthin"],"prefix":"10.1248","volume":"40","author":[{"given":"Gyujin","family":"Park","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Horie","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakeru","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Onishi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Iezaki","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"},{"name":"Venture Business Laboratory, Organization of Frontier Science and Innovation, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Citrus Research Division, Institute of Fruit Tree and Tea Science, National Agriculture and Food Research Organization"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Hinoi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Sugiura M. beta-Cryptoxanthin and the risk for lifestyle-related disease: findings from recent nutritional epidemiologic studies. <i>Yakugaku Zasshi<\/i>, <b>135<\/b>, 67\u201376 (2015)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Burri BJ. Beta-cryptoxanthin as a source of vitamin A. <i>J. Sci. Food Agric.<\/i>, <b>95<\/b>, 1786\u20131794 (2015).","DOI":"10.1002\/jsfa.6942"},{"key":"3","unstructured":"3) Sugiura M. beta-Cryptoxanthin and the risk for lifestyle-related disease: findings from recent nutritional epidemiologic studies. <i>Yakugaku Zasshi<\/i>, <b>135<\/b>, 67\u201376 (2015)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ozaki K, Okamoto M, Fukasawa K, Iezaki T, Onishi Y, Yoneda Y, Sugiura M, Hinoi E. Daily intake of beta-cryptoxanthin prevents bone loss by preferential disturbance of osteoclastic activation in ovariectomized mice. <i>J. Pharmacol. Sci.<\/i>, <b>129<\/b>, 72\u201377 (2015).","DOI":"10.1016\/j.jphs.2015.08.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Park G, Horie T, Iezaki T, Okamoto M, Fukasawa K, Kanayama T, Ozaki K, Onishi Y, Sugiura M, Hinoi E. Daily oral intake of beta-cryptoxanthin ameliorates neuropathic pain. <i>Biosci. Biotechnol. Biochem.<\/i>, <b>81<\/b>, 1014\u20131017 (2017).","DOI":"10.1080\/09168451.2017.1280661"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Shen J, Chen D. Recent progress in osteoarthritis research. <i>J. Am. Acad. Orthop. Surg.<\/i>, <b>22<\/b>, 467\u2013468 (2014).","DOI":"10.5435\/JAAOS-22-07-467"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tsezou A. Osteoarthritis year in review 2014: genetics and genomics. <i>Osteoarthritis and cartilage\/OARS, Osteoarthritis Research Society<\/i>, <b>22<\/b>, 2017\u20132024 (2014).","DOI":"10.1016\/j.joca.2014.07.024"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Clegg DO, Reda DJ, Harris CL, Klein MA, O\u2019Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. <i>N. Engl. J. Med.<\/i>, <b>354<\/b>, 795\u2013808 (2006).","DOI":"10.1056\/NEJMoa052771"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. <i>Drugs Aging<\/i>, <b>24<\/b>, 573\u2013580 (2007).","DOI":"10.2165\/00002512-200724070-00005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Vasiliadis HS, Tsikopoulos K. Glucosamine and chondroitin for the treatment of osteoarthritis. <i>World J. Orthop.<\/i>, <b>8<\/b>, 1\u201311 (2017).","DOI":"10.5312\/wjo.v8.i1.1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kobori M, Ni Y, Takahashi Y, Watanabe N, Sugiura M, Ogawa K, Nagashimada M, Kaneko S, Naito S, Ota T. beta-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice. <i>PLOS ONE<\/i>, <b>9<\/b>, e98294 (2014).","DOI":"10.1371\/journal.pone.0098294"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Iezaki T, Ozaki K, Fukasawa K, Inoue M, Kitajima S, Muneta T, Takeda S, Fujita H, Onishi Y, Horie T, Yoneda Y, Takarada T, Hinoi E. ATF3 deficiency in chondrocytes alleviates osteoarthritis development. <i>J. Pathol.<\/i>, <b>239<\/b>, 426\u2013437 (2016).","DOI":"10.1002\/path.4739"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the mouse. <i>Osteoarthritis and cartilage\/OARS, Osteoarthritis Research Society<\/i>, <b>18<\/b> (Suppl. 3), S17\u2013S23 (2010).","DOI":"10.1016\/j.joca.2010.05.025"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Wang L, Hinoi E, Takemori A, Takarada T, Yoneda Y. Abolition of chondral mineralization by group III metabotropic glutamate receptors expressed in rodent cartilage. <i>Br. J. Pharmacol.<\/i>, <b>146<\/b>, 732\u2013743 (2005).","DOI":"10.1038\/sj.bjp.0706358"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yamamoto T, Hinoi E, Fujita H, Iezaki T, Takahata Y, Takamori M, Yoneda Y. The natural polyamines spermidine and spermine prevent bone loss through preferential disruption of osteoclastic activation in ovariectomized mice. <i>Br. J. Pharmacol.<\/i>, <b>166<\/b>, 1084\u20131096 (2012).","DOI":"10.1111\/j.1476-5381.2012.01856.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Fujimori S, Hinoi E, Yoneda Y. Functional GABA(B) receptors expressed in cultured calvarial osteoblasts. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>293<\/b>, 1445\u20131452 (2002).","DOI":"10.1016\/S0006-291X(02)00405-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, Griggs DW. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. <i>Arthritis Rheum.<\/i>, <b>56<\/b>, 575\u2013585 (2007).","DOI":"10.1002\/art.22334"},{"key":"18","unstructured":"18) Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Yano M. High serum carotenoids associated with lower risk for bone loss and osteoporosis in post-menopausal Japanese female subjects: prospective cohort study. <i>PLOS ONE<\/i>, <b>7<\/b>, e52643 (2012)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Imada K, Tsuchida A, Ogawa K, Sofat N, Nagase H, Ito A, Sato T. Anti-arthritic actions of beta-cryptoxanthin against the degradation of articular cartilage <i>in vivo<\/i> and <i>in vitro.<\/i> <i>Biochem. Biophys. Res. Commun.<\/i>, <b>476<\/b>, 352\u2013358 (2016).","DOI":"10.1016\/j.bbrc.2016.05.126"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tsuruha J, Masuko-Hongo K, Kato T, Sakata M, Nakamura H, Nishioka K. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis. <i>Arthritis Rheum.<\/i>, <b>44<\/b>, 838\u2013845 (2001).","DOI":"10.1002\/1529-0131(200104)44:4<838::AID-ANR140>3.3.CO;2-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Pap T, Korb-Pap A. Cartilage damage in osteoarthritis and rheumatoid arthritis\u2013two unequal siblings. <i>Nat. Rev. Rheumatology<\/i>, <b>11<\/b>, 606\u2013615 (2015).","DOI":"10.1038\/nrrheum.2015.95"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wang M, Sampson ER, Jin H, Li J, Ke QH, Im HJ, Chen D. MMP13 is a critical target gene during the progression of osteoarthritis. <i>Arthritis Res. Ther.<\/i>, <b>15<\/b>, R5 (2013).","DOI":"10.1186\/ar4133"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/7\/40_b17-00161\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T02:29:03Z","timestamp":1569637743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/7\/40_b17-00161\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00161","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}